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Unlike plant viruses, most mammalian, insect, and
bacterial viruses attach to specific cellular receptors
that, in part, determine host range and tissue tropism.
Viruses have evolved to utilize a wide variety of cell-
surface molecules as their receptors, which include pro-
teins, carbohydrates, and glycolipids. Some viruses rec-
ognize very specific molecules, such as the intercellular
adhesion molecule-1 (ICAM-1; CD54), the receptor rec-
ognized by a large group of rhinoviruses, whereas other
viruses recognize widely distributed chemical groups,
such as sialic acid moieties by influenza viruses. The
tissue distribution of the receptor, in part, determines
virus tropism and, hence, the symptoms of the infection.
Similarly, species differences between receptor mole-
cules can limit host range. For instance, only humans
and apes are susceptible to rhinovirus infections, a prop-
erty correlated with the inability of human rhinoviruses
(HRVs) to bind to the receptor ICAM-1 molecule in other
species.
Despite extensive similarities in sequence, structure,
and physical properties among picornaviruses, suggest-
ing evolution from a common ancestor (Rossmann et al.,
1985; Palmenberg, 1989; Rueckert, 1990), they neverthe-
less recognize a variety of receptors. Possibly a primor-
dial virus was able to bind weakly to a large number
of different molecules. Subsequently, different viruses
evolved that were progressively more efficient at recog-
nizing particular molecules as a means to infect specific
cells. Indeed, the grouping of picornaviruses might sug-
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239gest such a scenario. All polioviruses (PVs) appear to
recognize human CD155 [“poliovirus receptor” (Mendel-
sohn et al., 1989)] and many coxsackie B viruses recog-
nize coxsackie-adenovirus receptor (CAR), whereas cer-
tain echoviruses recognize decay-accelerating factor
(DAF; CD55). It is surprising, therefore, that rhinovirus
serotypes can be divided into roughly three groups, each
group recognizing a different cellular receptor molecule
(Abraham and Colonno, 1984; Uncapher et al., 1991). The
receptor for the major group of rhinoviruses, ICAM-1,
belongs to the immunoglobulin (Ig) superfamily (Greve et
al., 1989; Staunton et al., 1989), whereas the receptor for
the minor group is the low-density lipoprotein (LDL) re-
ceptor (Hofer et al., 1994).
Receptor binding is just the first step in infection. The
virus or maybe only the genome then enters the cell in a
process that requires translocation of the viral genome
or a subviral particle across the membrane into the
cytoplasm, and sometimes into the nucleus. Since ge-
nome delivery requires or accompanies major rear-
rangements of the capsid structure, entry must be a
tightly regulated process, which is triggered by the cell.
The mechanism of entry, for example for enveloped vi-
ruses, requires fusion of the viral envelope with the
limiting cellular membrane. Nonenveloped viruses such
as picornaviruses (Rueckert, 1990) enter the cytoplasm in
a manner that has not been well elucidated, though it
must differ significantly in detail from the membrane-
fusion strategy adopted by enveloped viruses.
II. PICORNAVIRUSES AND THE
CANYON HYPOTHESIS
Picornaviruses are small, icosahedral, nonenveloped
viruses with a plus-sense RNA genome. They are among
the most common animal virus pathogens and include
HRVs and PVs. High-resolution structures have been
determined for a variety of HRV and PV serotypes by
means of X-ray crystallography (Hogle et al., 1985; Ross-
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240 MINIREVIEWmann et al., 1985). The capsids are structurally quite
imilar, but HRVs and PVs differ in both their pathology
nd stability (HRVs are unstable below pH 6). Thus, PVs
an survive in the stomach and intestines, whereas rhi-
oviruses thrive primarily in the upper respiratory sys-
em. Virions are about 8.5 3 106 daltons in mass, have an
external diameter of ;300 Å, and contain 60 protomers,
each of which is made up of four polypeptides, VP1–VP4.
The first three of these viral proteins reside on the exte-
rior of the virus and make up its spherical protein shell.
The three PV serotypes all recognize the same cellular
receptor molecule, CD155 (Mendelsohn et al., 1989;
oike et al., 1990; Wimmer et al., 1994). At least 78 of the
ore than 100 HRV serotypes recognize ICAM-1 as a
ellular receptor, and other picornaviruses recognize a
ariety of different cell-surface molecules (Rueckert,
996). Although ICAM-1 is known to be involved in ad-
esion of lymphocytes to damaged or infected cells, the
ormal function of CD155 is uncertain.
The capsids of rhino- and enteroviruses have a narrow
urface depression (“canyon”) that surrounds each of the
FIG. 1. Comparison of the mature structures of ICAM-1, the receptor f
monkey PV receptor (mCD155), and the murine poliovirus receptor-rela
The number of amino acids is shown for each domain. [Reprinted with p2 fivefold vertices. Rhinovirus receptors were predicted
o be long, narrow molecules that could bind to con-served residues within the canyon (Rossmann et al.,
1985). This mode of binding would permit the virus to
escape host immune surveillance because bulkier neu-
tralizing antibodies should be unable to enter the can-
yon. This prediction turned out to be correct with regard
to the site of receptor binding in the canyon and the
shape of the receptor for the major group of rhinoviruses
(Olson et al., 1993; Kolatkar et al., 1999) and for poliovi-
ruses (Belnap et al., 2000a; He et al., 2000). However, the
rationale of the prediction was questioned when the
footprint of a neutralizing antibody was found to extend
beyond the rims of the canyon (Smith et al., 1996) even
though naturally selected, escape mutations that pre-
vented antibody neutralization were located on the viral
surface well outside the canyon (Rossmann et al., 1985;
Sherry and Rueckert, 1985).
CD155 and ICAM-1 are membrane-anchored, single-
span glycoproteins whose extracellular regions consist
of three and five domains, respectively, each with Ig-like
folds (Fig. 1). The amino-terminal domain, D1, in both
CD155 (Freistadt and Racaniello, 1991; Koike et al., 1991;
ajor group of rhinoviruses, with the human PV receptor (hCD155), the
tein 2 (mPRR2). Sites of glycosylation are indicated by shaded circles.
on from He et al. (1999) Copyright National Academy of Sciences.]or the mSelinka et al., 1991) and ICAM-1 (Staunton et al., 1990;
McClelland et al., 1991; Register et al., 1991) contains the
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241MINIREVIEWvirus recognition site. Hence, virus attachment occurs at
a site on the receptor that is distal from the plasma
membrane. This property may be important for success-
ful initiation of infection of cells by viruses and may
reflect the enhanced ability of the N-terminal Ig domain
to penetrate into the picornaviral canyon.
Ig superfamily domains have a structure that consists
of a b-barrel fold in which all b-strands (labeled A–G) run
arallel or antiparallel to the long axis of the domain. The
FIG. 2. (Right) The Ca backbone of domain D1 of CD155 based upon
based upon its crystallographic structure determination. Labeling of th
esidues are indicated.
T
Different IC
Type Residues Domains Mutations Expression system
1 1–185 D1–D2 Wild type CHO cells
2 1–185 D1–D2 N103 3 Q
N118 3 Q
N156 3 Q
Baculovirus-infected
SF9 cells
3b 1–190 D1–D2 Wild type Modified CHO cells
Lec3.2.8.1c
4 1–453 D1–D5 Wild type CHO cells
a The Asn to Gln mutations in type 2 ICAM-1 remove three out of fou
CAM-1 expression produces mannose-only glycans with reduced hetb Two independent molecules per crystallographic asymmetric unit, referre
c (Casasnovas et al., 1998).old of the CD155 D1 domain resembles that of an Ig
ariable (V) domain [nomenclature reviewed by Chothia
nd Jones (1997)], whereas the fold of the ICAM-1 D1
omain is intermediate (I) between the variable and
onstant (C) Ig folds (Fig. 2). An Ig-like V domain has two
xtra b-strands, labeled C9 and C0, between b-strands C
and D. Thus, compared to ICAM-1, the D1 domain of
CD155 has 32 more residues. D1 in CD155 also has two
potential glycosylation sites, whereas the ICAM-1 D1
ology to protein zero. (Left) The Ca backbone of domain D1 of ICAM-1
ands, the sites of potential glycosylation, and strategically numbered
Fragments
Glycosylationa Crystal structure
Protein Data Bank
id code
ll, complex (Kolatkar et al., 1999) 1D3L
duced, complex (Bella et al., 1998) 1IAM
ll, high-mannose (Casasnovas et al., 1998) 1IC1
ll, complex — —
sylation sites in ICAM-1 D2; the mutant CHO cell line used for type 3
eity.its hom
e b-strABLE 1
AM-1
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242 MINIREVIEWlacks glycosylation. Absence of carbohydrate in CD155
D1 is known to enhance its binding to PV (Bernhardt et
al., 1994).
Cell entry and uncoating are initiated when PV and
RV recognize their respective receptors (Koike et al.,
1992; Rossmann, 1994; Belnap et al., 2000b). Purified,
soluble receptor molecules, as well as the membrane-
anchored receptor, convert infectious virions to altered
(“A”) particles (135S) (Hoover-Litty and Greve, 1993; Wim-
mer et al., 1994). VP4 is absent in A particles, and the
N-terminus of VP1 is externalized (Fricks and Hogle,
1990). Slightly longer incubation leads to the formation of
80S particles, which are devoid of the genomic RNA. It is
uncertain, however, whether the 135S and 80S particles
are intermediates in the uncoating pathway (Curry et al.,
1996; Dove and Racaniello, 1997; Arita et al., 1998).
It has been suggested (Rossmann, 1994) that binding
of the receptor might expel a lipid moiety that resides in
a hydrophobic pocket within VP1, which is immediately
underneath the floor of the canyon, thereby destabilizing
the virion and, hence, initiating uncoating. Considerable
experimental data now exist that support this mecha-
nism: (i) antiviral compounds bound to the hydrophobic
pocket in VP1 inhibit uncoating in HRVs and PVs (Fox
et al., 1986); (ii) these antiviral compounds preclude cell
FIG. 3. Cryo-EM reconstructions for HRV16–type 1 ICAM-1 (in red)
nd HRV14–type 1 ICAM-1 (in blue) depict the density corresponding to
he ICAM-1 fragments. Positions of the icosahedral symmetry elements
re shown. A small angular difference in orientation of receptor relative
o the viral surface indicates a slightly different binding of ICAM-1 to
ach serotype. The main direction of variation is depicted schemati-
ally with a white arrow in the asymmetric unit representation (inset),
oughly parallel to the canyon depression. The edge of the canyon
earest to the fivefold axis is defined as the “north wall.” The positions
f VP1 (blue), VP2 (green), and VP3 (red) are also shown diagrammat-
cally. [Reprinted with permission from Kolatkar et al. (1999) Copyright
European Molecular Biology Organization.]binding in many of the major-group HRVs (Pevear et al.,
1989, 1992); (iii) HRV antiviral escape mutants may in-FIG. 4. (a) Stereo view of the cryo-EM reconstruction showing the
complex of PV1(M) with human CD155. The outline of one icosahedral
asymmetric unit is shown. Note that the receptor leans in a southeast
direction. (b) Stereo view of the cryo-EM reconstruction showing the
complex of HRV16 with its ICAM-1 receptor [from Kolatkar et al. (1999)].
he outline of one icosahedral asymmetric unit is shown. Here the recep-
or leans southwest. (c) Stereo view of a cryo-EM reconstruction of PV, also
howing the icosahedral asymmetric unit. The asymmetric shape of the
anyon is noted by the most southerly point situated slightly east of center
arrow) and the smaller peak southwest of the canyon (arrow). These
eatures establish the correct hand of the reconstructions in (a) and (b) and
re consistent with the X-ray results, where the absolute hand is known.
d) Density (green) representing one CD155 molecule fitted with the Ca
backbone structure of the closest homologous structures found in the PDB
for each of the three domains. The difference map (blue) between the
cryo-EM density and the unglycosylated CD155 model shows the sites of
glycosylation. Potential glycosylation sites are depicted on the CD155
backbone (red). [Reprinted with permission from He et al. (2000) Copyright
National Academy of Sciences.]
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243MINIREVIEWvolve changes in residues either at the surface of the
canyon or in the hydrophobic pocket, thereby either in-
creasing the affinity of the virus for its receptor or de-
creasing the affinity of antiviral compounds for the virus
(Hadfield et al., 1995); (iv) HRV14 is able to externalize
oth VP4 and the N-terminus of VP1 in a spontaneous,
robably reversible manner (“breathing”), as shown by
imited proteolysis followed by mass spectroscopy
Lewis et al., 1998); (v) antibodies against internal
pitopes on VP1 and VP4 cause PV neutralization, also
uggesting a breathing mechanism for PVs (Li et al.,
994); (vi) HRV14 breathing is largely inhibited by antiviral
ompounds (Lewis et al., 1998); (vii) there is kinetic
vidence for two binding modes of ICAM-1 on the sur-
ace of HRVs (Casasnovas and Springer, 1995); and (viii)
FIG. 5. (a) Stereo diagram of a portion of the HRV16–type 2 ICAM
wo-domain ICAM-1 fragment. Superimposed, in yellow, is the differenc
mostly deglycosylated) reconstructions. The density in the HRV16–type
f the ICAM-1 fragments. (b) Fitting of the refined type 1 ICAM-1 mode
rotein is represented in grayscale, and the disordered carbohydrates
D1 to D3 of ICAM-1, manually fitted into the HRV16–type 4 ICAM-1
Additional lumps of electron density correspond to the predicted positio
density map shown in (a) and the refined ICAM-1 D1D2 model in (b)
olecular Biology Organization.]omplexes between HRVs and soluble receptors can be
btained as metastable entities that can be visualized by
t
Xryoelectron microscopy (cryo-EM), and subsequent
hanges in temperature, pH, or receptor concentration
rigger an irreversible uncoating step (Hoover-Litty and
reve, 1993; Olson et al., 1993). In spite of this seeming
ealth of data, the precise details of the interaction of
RVs with ICAM-1 and PVs with CD155 and the se-
uence of events that lead to uncoating remain to be
onfirmed.
III. CRYO-EM OF VIRUS–RECEPTOR COMPLEXES
Cryo-EM and X-ray crystallography, in conjunction with
tomic modeling, have been used to examine the inter-
ctions of ICAM-1 with two different HRV serotypes
Bella et al., 1998; Kolatkar et al., 1999) and the interac-
-EM reconstruction corresponding to the density (light blue) for the
ity map between HRV16–type 1 (fully glycosylated) and HRV16–type 2
struction has been suitably scaled to account for the lower occupancy
he cryo-EM reconstruction of the HRV16–type 1 ICAM-1 complex. The
resented by an ensemble of conformations (yellow). (c) A Ca model of
ruction. D2 coordinates were used to model domain D3 of ICAM-1.
o carbohydrate moieties on ICAM-1 D2, consistent with the difference
inted with permission from Kolatkar et al. (1999) Copyright European-1 cryo
e dens
2 recon
l into t
are rep
reconst
ns for twions of CD155 with PV serotype 1 (Belnap et al., 2000a;
ing et al., 2000; He et al., 2000). The structure of each
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244 MINIREVIEWcomplex was modeled at atomic resolution by fitting
appropriate crystallographic structures of the virus and
of the receptor to cryo-EM density maps. The fitting
of each virus was a straightforward procedure because
all that was required was, first, to orient the X-ray and EM
structures to superimpose the known icosahedral sym-
metry elements and, second, to radially scale the EM
map to match the X-ray structure. The EM and crystallo-
graphic density maps, when calculated to similar reso-
lution limits, exhibit excellent agreement and, hence,
validate the fitting process. Radial scaling of the cryo-EM
density map to the crystallographic structure of the virus
(Rossmann, 2000) compensates for uncertainties in the
absolute magnification of EM images, which can vary up
to several percent from the nominal values recorded at
the time of microscopy (Olson and Baker, 1989). How-
ever, the fitting of crystallographically determined viral
receptor structures to the corresponding density features
in cryo-EM maps of virus–receptor complexes was a
more difficult process.
The domain structures of ICAM-1 and homologous
structures of CD155 are well known, but the elbow an-
gles between the domains in each receptor can vary
considerably. In addition, the atomic fitting procedure
had to proceed such that steric clashes with the virus
were minimized, though recognizing that formation of the
complex might have been accompanied by conforma-
tional changes in either virus or receptor. The orientation
and positional indicators, such as glycosylation sites,
helped guide the accurate positioning of crystallographic
models within the cryo-EM density maps. The combina-
tion of cryo-EM and crystallographic data yielded an
accuracy of better than 2 Å in positioning individual
eceptor domains with respect to the virus surface. As
he separation between consecutive Ca atoms in a
polypeptide is 3.8 Å, the accuracy of positioning the
receptor molecule was sufficient to identify the putative
chemical interactions between the amino acids of the
receptor and viral surface.
Interactions of various ICAM-1 derivatives (Table 1)
with two rather different HRV serotypes are similar in that
the orientations of the long ICAM-1 molecule relative to
the viral surface differ by only 2 or 3°(Fig. 3). Interaction
of CD155 with PV1 is very different from ICAM-1 with
HRV (Belnap et al., 2000a; Xing et al., 2000; He et al.,
2000), although the two receptors bind to similar sites
within the canyons (Fig. 4). ICAM-1 also binds into the
coxsackievirus A21 canyon, but in a quite different ori-
entation from that seen in HRV or of CD155 into the PV
canyon (Xiao, Bowman, Baker, Kuhn, and Rossmann,
unpublished results). Thus, the sites of receptor binding
within the canyon are conserved among entero- and
rhinoviruses, and the receptors are long, slender, flexible
molecules, although their orientations on the viral sur-
faces can vary considerably.
H
cIV. STRUCTURES OF THE RECEPTOR MOLECULES
The atomic structure of the amino-terminal two do-
mains, D1D2, of ICAM-1 has been determined in inde-
pendent crystallographic studies (Casasnovas et al.,
1998; Kolatkar et al., 1999) (Table 1). Also, the structure of
a mostly deglycosylated ICAM-1 D1D2 fragment (resi-
dues 1–185, type 2, Table 1) (Bella et al., 1998) has been
established. Four independent versions of the D1D2
ICAM-1 fragment in the three available crystal structures
(Table 1) each contain a different elbow angle, with the
variation occurring mostly in one plane. This restricted
variation exists despite differences in the crystal packing
environments and glycosylation properties. The lack of a
spacer region between D1 and D2 permits several close
interactions between the two domains and appears to be
the basis for the restricted flexibility. This restriction sig-
nificantly reduced the number and range of search pa-
rameters required to fit the ICAM-1 structure to the
cryo-EM density maps. The structure of the PV receptor,
CD155, has yet to be determined at high resolution.
However, model building, based on known homologous
structures, has provided some preliminary structural in-
sights (Belnap et al., 2000a; Xing et al., 2000; He et al.,
2000).
V. RECEPTOR GLYCOSYLATION SITES GUIDE
ORIENTATION DETERMINATION
Cryo-EM density maps provide direct evidence for the
resence and location of carbohydrate moieties on the
eceptor molecules and thereby help confirm and im-
rove the accuracy of fitting receptor molecule atomic
odels into the cryo-EM reconstructions. Cryo-EM re-
onstruction of HRV16 complexed with fully glycosylated
1D2 ICAM-1 (type 1, Table 1) and mostly unglycosylated
1D2 ICAM-1 (type 2, Table 1) was used to produce a
ifference map (Fig. 5) that identified the three deglyco-
ylated sites and thus confirmed the fit of the D1D2
CAM-1 structure into the electron density for the virus–
eceptor complex.
Although only the glycosylated form of CD155 was
sed to study PV1–CD155 complexes by cryo-EM re-
onstruction, He et al. (2000) used a model of the
nglycosylated CD155 fitted to the cryo-EM density to
roduce a difference map (Fig. 4) to confirm fit of the
odel to the cryo-EM map (He et al., 2000). Belnap et
l. (2000a) used the “bumps” on the receptor mole-
ules protruding from the viral surface to identify the
lycosylation sites.
VI. THE FOOTPRINT OF THE RECEPTOR
ON THE VIRAL SURFACE
The tip of ICAM-1 D1 and the canyon wall and floor of
RV16 and HRV14 exhibit extensive shape and charge
omplementarity (Kolatkar et al., 1999). HRVs bind to
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245MINIREVIEWICAM-1, but not to other homologous molecules, such as
ICAM-2 or ICAM-3. This specificity has been rationalized
by the crystallographic and sequence analysis of the BC,
DE, and FG loops in domain D1, which differ in sequence
and conformation (Bella et al., 1998). Minor-group HRVs,
hich do not bind ICAM-1, are not obviously phylogeneti-
ally or structurally distinct from the major-group HRVs.
urthermore, HRV14, a major-group serotype, is more
istantly related to another major-group serotype,
RV16, than to the minor-group HRV1A and HRV2 sero-
ypes (whose structures are known). Nevertheless, the
esidues of HRV2 corresponding to the ICAM-1 footprint
n HRV14 or HRV16 lack the charge complementarity
bserved for the major-group HRVs (J. Bella, N. Verda-
uer, I. Fita, and M. G. Rossmann, in preparation).
The viral and receptor surfaces involved in the inter-
ace between CD155 and PV1 are in excellent agreement
ith mutational data (Bernhardt et al., 1994; Colston and
acaniello, 1994; Morrison et al., 1994; Harber et al.,
1995; Liao and Racaniello, 1997) and, hence, validate the
accuracy of the model-building study (Belnap et al.,
2000a; He et al., 2000). Unlike ICAM-1, which contacts
rimarily the floor and south wall of the HRV canyon,
D155 overlaps the north and south walls as well as the
loor of the PV canyon. Since the D1 domain of CD155
dopts a more tangential orientation relative to the virus
urface than ICAM-1, much of its C,C9,C0 face makes
dditional, extensive contact with the PV surface. Utiliza-
ion of the C,C9,C0 face by CD155 for interaction with its
iral ligand is similar in this respect to CD4 with HIV
Kwong et al., 1998). The CD155 footprint occupies about
300 Å2 of the PV surface, whereas the ICAM-1 footprint
on HRVs covers only 900 Å2 (Kolatkar et al., 1999). The
arger CD155 footprint is a consequence of the contacts
ade between the additional C,C9,C0 surface of CD155
nd the viral surface.
VII. POSSIBLE MECHANISMS FOR RECEPTOR-
INDUCED VIRAL UNCOATING
Substantial evidence [see Section II on canyon hy-
othesis (Kolatkar et al., 1999)] suggests that the struc-
tures observed for the HRV–ICAM-1 complexes repre-
sent an initial recognition event. Only subsequently is the
receptor likely to bind deeper within the canyon and
thereby possibly compete out the lipid moiety in the VP1
pocket (Rossmann, 1994) (Fig. 6). Loss of “pocket factor”
then presumably leads to virus destabilization and pro-
gressive disassembly and release of the genomic RNA.
CD155 binding may follow a similar pathway, as evi-
denced in EM by the substantial loss of particles upon
incubation of PV with soluble CD155 (He et al., 2000). It
has been speculated (Kolatkar et al., 1999) that the nat-
ural breathing of picornaviruses (Lewis et al., 1998) might
facilitate receptor binding to both the north and south
walls of the canyon and, thus, maintain a channel alongthe fivefold axis to permit the externalization of VP4, the
amino end of VP1, and, eventually, the RNA. For PV, the
receptor already appears to contact both walls of the
canyon in the initial recognition event. The presence of
CD155, therefore, may simply prevent natural breathing
in PV and keep pores open as the receptor binds deeper
into the canyon.
FIG. 6. Schematic representation of a proposed two-step binding
mechanism between ICAM-1 and major-group HRVs. ICAM-1 is repre-
sented only as a two-domain fragment. (a) The first (observed) step
corresponds to the cryo-EM reconstructions of HRV–ICAM-1 fragments
in which ICAM-1 binds primarily to the floor and south wall of the
canyon; (b) the second (hypothesized) step involves a conformational
change in the virus surface, shown only on the right-hand side of the
diagram. Probably both walls and the floor of the canyon bind to
domain D1 of ICAM-1 and, in so doing, open up the fivefold channel.
This requires conformational flexibility of VP1, which forms a large part
of both the north and south walls of the canyon, and probably also an
empty hydrophobic pocket in VP1. Opening of the pentamer vertex,
induced by the binding of one or more ICAM-1 molecules, may facilitate
externalization of VP4 and other internal viral components, including
RNA. [Reprinted with permission from Kolatkar et al. (1999) Copyright
European Molecular Biology Organization.]The markedly different mode of interaction of CD155
with PV1, of ICAM-1 with HRVs, and of ICAM-1 with
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246 MINIREVIEWcoxsackievirus A21 might seem surprising. Neverthe-
less, these receptors share several common features:
they all bind into the picornavirus canyon, initiate uncoat-
ing, and are long, thin molecules that extend far from the
cell surface. The similar location of binding in the canyon
suggests that it is the site itself that is important, not the
orientation that the bound receptor adopts. The common
binding site is required to hide a part of the site from
neutralizing antibodies (Rossmann et al., 1985) and to
regulate virus stability by competition between the bind-
ing of receptor and the lipid-like pocket factor in VP1
(Oliveira, 1993; Rossmann, 1994). The apparent need to
utilize a receptor molecule that is long and extends far
from the cell surface may indicate a requirement for the
virus to bind to molecules that, by virtue of Brownian
motion, are mobile and, hence, promote binding of mul-
tiple receptors to unoccupied binding sites on the virus,
thereby facilitating cell entry and uncoating.
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